4-ethyl-N-[2-(4-methyl-thiazol-2-yl)-2H-pyrazol-3-yl]benzenesulfonamide | 1620335-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-ethyl-N-[2-(4-methyl-thiazol-2-yl)-2H-pyrazol-3-yl]benzenesulfonamide
• 英文别名: 4-ethyl-N-[2-(4-methyl-1,3-thiazol-2-yl)pyrazol-3-yl]benzenesulfonamide
• CAS: 1620335-86-5
• 化学式: C₁₅H₁₆N₄O₂S₂
• 分子量: 348.45
• InChiKey: PQHFXMDZFWZDLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES<br/>[FR] AGONISTES DU RÉCEPTEUR D'OXYTOCINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014111356A1

  公开（公告）日：2014-07-24

  The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A2 is phenyl; R2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O)2-lower alkyl substituted by halogen; n is 1 or 2; or a to pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawel, drug addiction and for the treatment of Prader-Willi Syndrom.

  该发明涉及使用式I的化合物，其中A1是苯基或含有1、2或3个杂原子（N或S）的五元或六元杂环烷基；R1是氢、低碳链基、卤素、被卤素取代的低碳链基或环烷基；A2是苯基；R2是卤素、低碳链基、被卤素取代的低碳链基、被卤素取代的低碳氧基、氰基、被卤素取代的S-低碳链基、被卤素取代的S（O）2-低碳链基；n为1或2；或其药学上可接受的酸盐，用于治疗自闭症、压力（包括创伤后应激障碍）、焦虑（包括焦虑症和抑郁症）、精神分裂症、精神障碍和记忆丧失、酒精戒断、药物成瘾以及普拉德-威利综合征。
• Oxytocin receptor agonists for the treatment of CNS diseases
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20150322058A1

  公开（公告）日：2015-11-12

  The invention relates to the use of a compound of formula I wherein A 1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R 1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen or cycloalkyl; A 2 is phenyl; R 2 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, S-lower alkyl substituted by halogen, S(O) 2 -lower alkyl substituted by halogen; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of Prader-Willi Syndrome.

  本发明涉及使用公式I的化合物，其中A1是苯基或含有1、2或3个杂原子（选自N或S）的五元或六元杂环芳基基团；R1是氢、低碳基、卤素、低碳基卤素取代或环烷基；A2是苯基；R2是卤素、低碳基、低碳基卤素取代、低碳氧基卤素取代、氰基、S-低碳基卤素取代、S（O）2-低碳基卤素取代；n为1或2；或其药学上可接受的酸加盐、外消旋混合物或其对映异构体，用于治疗自闭症、压力（包括创伤后应激障碍）、焦虑（包括焦虑症和抑郁症）、精神分裂症、精神障碍和记忆丧失、酒精戒断、药物成瘾以及普拉德-威利综合征的治疗。
• OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2945624B1

  公开（公告）日：2018-04-18
• US9751870B2
  申请人：——

  公开号：US9751870B2

  公开（公告）日：2017-09-05